EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has made a 37.1% comeback from a 12-month low price of $1.24. It was seen 4.29% higher, changing the price to $1.7, when the closing bell rang on 6/12/2019. At a recent session, the prices were hovering between $1.46 and $1.66. This company shares are 257.65% off its target price of $6.08 and the current market capitalization stands at $190.26M. The recent change has given its price a 0.31% lead over SMA 50 and -56.85% deficit over its 52-week high. The stock witnessed -1.16% declines, -34.36% declines and -24.44% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EYPT’s volatility during a week at 8.29% and during a month it has been found around 6.64%.

EyePoint Pharmaceuticals, Inc. (EYPT) Top Holders

Institutional investors currently hold around $101 million or 62.1% in EYPT stock. Look at its top three institutional owners: Essex Woodlands Management, Inc. owns $68.31 million in EyePoint Pharmaceuticals, Inc., which represents roughly 35.9% of the company’s market cap and approximately 67.64% of the institutional ownership. Similar statistics are true for the second largest owner, Hightower Advisors, Llc, which owns 5,284,838 shares of the stock are valued at $8.61 million. The third largest holder is Vanguard Group Inc, which currently holds $4.55 million worth of this stock and that ownership represents nearly 2.39% of its market capitalization.

EyePoint Pharmaceuticals, Inc. 13F Filings

At the end of March reporting period, 38 institutional holders increased their position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by some 7,419,702 shares, 19 decreased positions by 652,223 and 7 held positions by 53,772,495. That puts total institutional holdings at 61,844,420 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 5,320,841 shares while 6 institutional investors sold out their entire positions totaling 80,722 shares.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Trades

Multiple company employees have indulged in significant insider trading. EyePoint Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Landis John B. has acquired 40,000 shares of EyePoint Pharmaceuticals, Inc. (EYPT) in the trading session dated May. 13, 2019. These shares are worth $69,600 and were traded at $1.74 each. The SEC filing shows that Duker Jay S. performed a purchase of 5,000 shares. The Director added these shares by way of transaction on Apr. 01, 2019. The company’s shares were assimilated at $1.89 per share worth to an investment of some $9,450 to the account of Duker Jay S..

President & CEO, Lurker Nancy, purchased 28,500 common shares of EyePoint Pharmaceuticals, Inc. (EYPT) in the open market. In a transaction dated Mar. 29, 2019, the shares were bought at an average price of $1.76, giving away a sum of $50,160. After this purchase, 240,200 common shares of EYPT are directly owned by the insider, with total stake valued at $408,340.

In the transaction dated Mar. 29, 2019, a great number of shares acquired came courtesy the Director; Godshall Douglas Evan added a total of 17,000 shares at an average price of $1.75, amounting to approximately $29,750. The insider now directly owns 29,500 shares worth $50,150.

EyePoint Pharmaceuticals, Inc. (EYPT) Analyst Guide

Several analysts have released their opinion on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].